| abstract |
(57) SUMMARY Disclosed are antibodies that specifically inhibit VEGF binding to only one of two VEGF receptors (VEGFR2). These antibodies efficiently inhibit angiogenesis and further have improved safety due to their specificity. Thus, the present invention provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic disorders. Advantageous immunoconjugate and prodrug compositions and methods of using these new VEGF-specific antibodies are also provided. |